Read by QxMD icon Read

Leukemia & Lymphoma

Christopher Pleyer, Adrian Wiestner, Clare Sun
Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interactions, modulating the T-cell compartment, and altering the cytokine milieu. Ibrutinib also partially restores T-cell and myeloid defects associated with CLL. In contrast, immune-related adverse effects, including pneumonitis, colitis, hepatotoxicity, and infections are of particular concern with idelalisib...
May 15, 2018: Leukemia & Lymphoma
Meera Yogarajah, Nathan Montgomery, Melissa Matson, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Katherine Pepin, Lori Vaught, Benyam Muluneh, Matthew C Foster, Joshua F Zeidner
No abstract text is available yet for this article.
May 11, 2018: Leukemia & Lymphoma
Igor A Olkhovskiy, Aleksey S Gorbenko, Marina A Stolyar, Evgeniy V Vasiliev, Mikhail A Mikhalev, Kseniya A Tabakova
No abstract text is available yet for this article.
May 11, 2018: Leukemia & Lymphoma
Juan Pablo Alderuccio, Nicholas Mackrides, Jennifer R Chapman, Francisco Vega, Izidore S Lossos
No abstract text is available yet for this article.
May 10, 2018: Leukemia & Lymphoma
Zofia Litwińska, Karolina Łuczkowska, Bogusław Machaliński
Extracellular vesicles (EVs) act as transporters that carry regulatory molecules between cells in physiologic and pathologic states; therefore, they play a crucial role in thrombosis, inflammation, angiogenesis, vascular dysfunction and other processes that affect the course of hematologic diseases. Within the tumor microenvironment, for example the leukemic bone marrow, EVs-mediated signaling may direct the activities of surrounding cells and act as a positive feedback loop that contributes to cancer progression...
May 10, 2018: Leukemia & Lymphoma
Maro Ohanian, Uri Rozovski, Rashmi Kanagal-Shamanna, Lynne V Abruzzo, Sanam Loghavi, Tapan Kadia, Andrew Futreal, Kapil Bhalla, Zhuang Zuo, Yang O Huh, Sean M Post, Peter Ruvolo, Guillermo Garcia-Manero, Michael Andreeff, Steven Kornblau, Gautam Borthakur, Peter Hu, L Jeffrey Medeiros, Koichi Takahashi, Marisa J Hornbaker, Jianhua Zhang, Graciela M Nogueras-González, Xuelin Huang, Srdan Verstovsek, Zeev Estrov, Sherry Pierce, Farhad Ravandi, Hagop M Kantarjian, Carlos E Bueso-Ramos, Jorge E Cortes
As new drugs targeting MYC show clinical activity in acute myeloid leukemia (AML), understanding MYC expression in AML is of critical importance. We assessed MYC protein expression by immunohistochemistry in bone marrow of patients with untreated AML (n = 265). Overall, 90% of patients demonstrated MYC overexpression and MYC immunopositivity ≤6% was associated with superior complete remission (CR) duration of 23 months versus 12 months for MYC immunopositivity >6% (p = .028). Among 241 patients at higher risk for relapse, including those ≥55 years of age and patients with intermediate- and high-risk AML, MYC immunopositivity ≤6% conferred significantly superior median overall survival (OS) (24 versus 13 months; p = ...
May 9, 2018: Leukemia & Lymphoma
Ayala Gover-Proaktor, Galit Granot, Metsada Pasmanik-Chor, Oren Pasvolsky, Saar Shapira, Oshrat Raz, Pia Raanani, Avi Leader
The tyrosine kinase inhibitors (TKIs), nilotinib, ponatinib, and dasatinib (but not bosutinib or imatinib), are associated with vascular adverse events (VAEs) in chronic myeloid leukemia (CML). Though the mechanism is inadequately understood, an effect on vascular cells has been suggested. We investigated the effect of imatinib, nilotinib, dasatinib, bosutinib, and ponatinib on tube formation, cell viability, and gene expression of human vascular endothelial cells (HUVECs). We found a distinct genetic profile in HUVECs treated with dasatinib, ponatinib, and nilotinib compared to bosutinib and imatinib, who resembled untreated samples...
May 9, 2018: Leukemia & Lymphoma
Yasuo Mori, Goichi Yoshimoto, Jun-Ichiro Yuda, Masayasu Hayashi, Jun Odawara, Takuro Kuriyama, Takeshi Sugio, Kohta Miyawaki, Kenjiro Kamezaki, Koji Kato, Katsuto Takenaka, Hiromi Iwasaki, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi
No abstract text is available yet for this article.
May 9, 2018: Leukemia & Lymphoma
Ayorinde Adehin, Babatunde A Adeagbo, Martin A Kennedy, Oluseye O Bolaji, Tiwalade A Olugbade, Rahman A Bolarinwa, Muheez A Durosinmi
Imatinib has been successful in the management of chronic myeloid leukemia (CML) but some patients experience adverse reactions or develop resistance to its use. The roles of some polymorphisms in genes encoding enzymes critical for the biotransformation of imatinib have been previously examined. This study, hence, evaluated some other unstudied functionally significant polymorphisms in CYP1A2, CYP2C8, CYP2C9, and CYP3A5. Trough imatinib blood levels and genotypes were determined in 42 CML patients by an HPLC-UV technique and a Sequenom iPLEX assay, respectively...
May 9, 2018: Leukemia & Lymphoma
Thomas Kristensen, Sigurd Broesby-Olsen, Hanne Vestergaard, Carsten Bindslev-Jensen, Charlotte Gotthard Mortz, Henrik Fomsgaard Kjaer, Michael Boe Møller
No abstract text is available yet for this article.
May 9, 2018: Leukemia & Lymphoma
Shaji Kumar, Brian Durie, Hareth Nahi, Ravi Vij, Meletios A Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Xavier Leleu, Meral Beksac, Hartmut Goldschmidt, Jens Hillengass, Zhuo Su, Brian Hutton, Chris Cameron, Imran Khan, Annette Lam
Daratumumab is a CD38-directed monoclonal antibody approved for treating multiple myeloma (MM). Propensity score matching (PSM) based on individual patient data (IPD) was conducted to compare overall survival (OS) and progression-free survival (PFS) for daratumumab versus real-world standard of care (SOC). IPD for patients with relapsed and refractory (RR) MM treated with daratumumab monotherapy were from the GEN501 and SIRIUS studies; IPD for patients treated with SOC were from an International Myeloma Working Group (IMWG) chart review of patients with RRMM...
May 9, 2018: Leukemia & Lymphoma
Tarsheen K Sethi, Nishitha M Reddy
Primary central nervous lymphoma (PCNSL) is a rare extra-nodal subtype of non-Hodgkin lymphoma and most cases are of diffuse large B-cell lymphoma histology with an aggressive presentation. The treatment of PCNSL has evolved over the years from radiation alone to multi-agent chemotherapy with the goal of minimizing long-term toxicity. Recent studies have evaluated autologous stem cell transplant as consolidation in eligible patients with success. The prognosis of relapsed disease remains poor and hence the emphasis is on effective and less toxic frontline strategies...
May 9, 2018: Leukemia & Lymphoma
Sreenivasulu Gunti, Sarah E M Herman, Raju V S R K Gottumukkala, Ying Xiong, Clare Sun, Gilberto N Carmona, Adrian Wiestner, Abner L Notkins
No abstract text is available yet for this article.
May 9, 2018: Leukemia & Lymphoma
Kathinka Krull, Marina Kunstreich, Annika Bronsema, Kirsten Bleckmann, Carl-Friedrich Classen, Bernhard Erdlenbruch, Norbert Jorch, Reinhard Kolb, Alfred Leipold, Olga Moser, Aram Prokop, Wolfram Scheurlen, Daniel Steinbach, Janina Klasen-Sansone, Dirk Klee, Gabriele Escherich, Anja Moericke, Martin Schrappe, Arndt Borkhardt, Michaela Kuhlen
Osteonecrosis (ON) is a common and debilitating side effect of anti-leukemic treatment in children with acute lymphoblastic leukemia (ALL). However, the impact of leukemia itself on ON development remains elusive. We analyzed 76 children enrolled in the ongoing OPAL trial, who had magnetic resonance imaging (MRI) studies at diagnosis. MRI screening revealed 14 osteonecrotic lesions (5 × hips, 9 × knees) of any grade (I-III) in 7 (9.2%) patients. Six months on, the number of ON per patient increased (1 patient), remained constant (2), and decreased (2)...
May 2, 2018: Leukemia & Lymphoma
Sameem Abedin, Leonidas C Platanias
No abstract text is available yet for this article.
May 2, 2018: Leukemia & Lymphoma
Konstantinos Dimopoulos, Helga Fibiger Munch-Petersen, Christian Winther Eskelund, Lene Dissing Sjö, Elisabeth Ralfkiaer, Peter Gimsing, Kirsten Grønbaek
The immunomodulatory drug thalidomide, and its analogs, lenalidomide, and pomalidomide (IMiDs), have become essential components of the standard treatment for multiple myeloma (MM), and have led to significant improvement of survival in patients with this devastating disease. Cereblon (CRBN), the direct target of IMiDs, has been proposed as a predictive biomarker of response to IMiDs. Using standard immunohistochemistry in formalin-fixed paraffin embedded (FFPE) bone marrow samples of 23 patients treated with a lenalidomide-containing regimen, we found that the malignant plasma cells of all the patients stained positive for CRBN, IKZF1, and IKZF3, regardless of sensitivity to IMiDs...
May 2, 2018: Leukemia & Lymphoma
Bastien Jamet, Clément Bailly, Thomas Carlier, Lucie Planche, Cyrille Touzeau, Françoise Kraeber-Bodéré, Philippe Moreau, Caroline Bodet-Milin
No abstract text is available yet for this article.
May 2, 2018: Leukemia & Lymphoma
Francesco Spina, Tommaso Radice, Chiara De Philippis, Martina Soldarini, Maria Chiara Di Chio, Anna Dodero, Anna Guidetti, Simonetta Viviani, Paolo Corradini
This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18-60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%)...
May 1, 2018: Leukemia & Lymphoma
Imo Akpan, Barbara Pro, Leonidas C Platanias
No abstract text is available yet for this article.
May 1, 2018: Leukemia & Lymphoma
Ethan B Ludmir, Sarah A Milgrom, Chelsea C Pinnix, Jillian R Gunther, Jason Westin, Yasuhiro Oki, Luis E Fayad, L Jeffrey Medeiros, Bouthaina S Dabaja, Loretta J Nastoupil
Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and central nervous system prophylaxis (CNS PPX). Fifty-two percent of patients received RT, and 28% received CNS PPX. Fourteen patients (56%) experienced recurrence, with 76% of relapses occurring ≥24 months after diagnosis, in contrast to reports supporting the use of 24-month event-free survival as a surrogate endpoint in the general DLBCL population...
April 26, 2018: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"